Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating in a report issued on Friday, ValuEngine reports.
A number of other analysts have also recently weighed in on the company. BidaskClub upgraded Ironwood Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Tuesday. Credit Suisse Group cut their target price on Ironwood Pharmaceuticals from $12.00 to $11.00 and set a "neutral" rating on the stock in a research report on Monday, June 1st. HC Wainwright cut their target price on Ironwood Pharmaceuticals from $13.00 to $11.00 and set a "neutral" rating on the stock in a research report on Monday, May 11th. Northland Securities assumed coverage on Ironwood Pharmaceuticals in a research report on Wednesday, June 17th. They set an "outperform" rating and a $14.00 target price on the stock. Finally, TheStreet cut Ironwood Pharmaceuticals from a "c" rating to a "d+" rating in a research report on Monday, May 11th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of "Hold" and a consensus price target of $12.13.
Ironwood Pharmaceuticals stock opened at $10.18 on Friday. Ironwood Pharmaceuticals has a 1-year low of $7.91 and a 1-year high of $14.10. The stock has a market cap of $1.64 billion, a PE ratio of 19.21 and a beta of 1.43. The stock's fifty day moving average is $10.31 and its two-hundred day moving average is $11.23.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.04 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.05 by ($0.01). Ironwood Pharmaceuticals had a net margin of 19.14% and a negative return on equity of 96.13%. The business had revenue of $79.94 million during the quarter, compared to analyst estimates of $78.62 million. During the same quarter in the prior year, the business earned ($0.26) earnings per share. The firm's quarterly revenue was up 16.3% on a year-over-year basis. As a group, analysts anticipate that Ironwood Pharmaceuticals will post 0.42 earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. Strs Ohio acquired a new position in Ironwood Pharmaceuticals in the 1st quarter valued at about $29,000. Amundi Pioneer Asset Management Inc. purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at approximately $63,000. AJO LP purchased a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $89,000. Neo Ivy Capital Management purchased a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $134,000. Finally, Balyasny Asset Management LLC purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at approximately $129,000.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.
Recommended Story: Market Timing - The Benefits and the Danger
To view ValuEngine's full report, visit ValuEngine's official website.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks That Risk-Averse Investors Can Buy Now
If the title of this presentation piqued your interest, then you understand that there’s no such thing as risk-free investing. And that’s particularly true when you’re investing in stocks. The truth is sometimes the best thing that can happen is that your portfolio performs less badly than the market.
The goal of the risk-averse investor is not to avoid stocks, it’s to ensure that you retain the capital you gain, even if that means your portfolio does not grow as fast or as far as more aggressive stocks. You have to have a very low FOMO (fear of missing out) level.
With that in mind, there are still ways you can profit from this market without throwing caution to the wind. One is to look for stocks that have a low beta. Beta is a measure of a stock’s volatility in comparison to the rest of the market. A stock with a beta of 1, for example, means that investors can expect the price movement of the stock to be closely correlated to the market. A beta of more than 1 means the stock price will be more volatile (higher highs but lower lows).
What you’re looking for is a beta of less than 1. This means that the stock is less volatile than the broader market. While this may mean lower highs, it also generally means lower lows.
And many of these stocks are in defensive sectors. This means that their performance is consistent under both good and bad economic conditions.
View the "7 Stocks That Risk-Averse Investors Can Buy Now".